Group One Trading, L.P. Hepion Pharmaceuticals, Inc. Transaction History

Group One Trading, L.P.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.31 - $1.06 $3,474 - $11,880	-11,208 Reduced 46.06%	13,128 $10,000
Q4 2022 Feb 09, 2023	SELL	$0.27 - $11.9 $513 - $22,610	-1,900 Reduced 7.24%	24,336 $7,000
Q3 2022 Nov 09, 2022	BUY	$0.51 - $10.4 $357 - $7,280	700 Added 2.74%	26,236 $13,000
Q2 2022 Aug 11, 2022	SELL	$0.57 - $1.22 $12,749 - $27,287	-22,367 Reduced 46.69%	25,536 $15,000
Q1 2022 May 12, 2022	BUY	$0.93 - $1.29 $6,926 - $9,607	7,448 Added 18.41%	47,903 $62,000
Q4 2021 Feb 11, 2022	BUY	$1.14 - $1.58 $13,487 - $18,692	11,831 Added 41.33%	40,455 $46,000
Q3 2021 Nov 12, 2021	SELL	$1.39 - $2.1 $66,824 - $100,957	-48,075 Reduced 62.68%	28,624 $44,000
Q2 2021 Aug 10, 2021	SELL	$1.56 - $2.26 $45,664 - $66,154	-29,272 Reduced 27.62%	76,699 $152,000
Q1 2021 May 12, 2021	BUY	$1.77 - $2.98 $179,603 - $302,383	101,471 Added 2254.91%	105,971 $195,000
Q4 2020 Feb 10, 2021	BUY	$1.58 - $3.64 $7,110 - $16,380	4,500 New	4,500 $10,000

Ticker HEPA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,229,600
Market Cap $37.4M
Description
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver...

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

Stay updated on Group One Trading, L.P. with notifications on news.